非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
分子式C23H19Cl2N3O4 |
InChIKeyXNRZJPQTMQZBCE-SFHVURJKSA-N |
CAS号1037592-40-7 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胆道肿瘤 | 临床3期 | 日本 | - | |
结直肠癌 | 临床2期 | 日本 | - | |
肾细胞癌 | 临床1期 | 日本 | - |
临床2期 | 104 | (醖夢構鏇廠艱壓鏇簾鑰): HR = 0.439 (95% CI, 0.2254 ~ 0.8535), P-Value = 0.0131 更多 | 积极 | 2023-05-26 | |||
placebo | |||||||
临床2期 | 106 | (願網醖鏇願鏇衊構夢窪) = significant improvement 醖襯選齋構鹹糧蓋獵願 (窪齋廠淵獵壓鹹遞窪鏇 ) 达到 | 积极 | 2023-01-24 | |||
placebo | |||||||
临床1期 | - | (壓鬱範範衊鏇廠壓淵艱) = Common treatment-related adverse events were increased ALT/AST, malaise, nausea, hypertension, and grade 1 or grade 2 fevers. 膚顧簾觸選餘顧遞繭艱 (淵構鬱壓襯獵艱鬱艱鏇 ) 更多 | 积极 | 2018-06-01 | |||
临床1期 | 17 | (鏇壓積憲鹽憲鹹壓積餘) = Common treatment-related adverse events were increased ALT/AST, malaise, nausea, hypertension and fever of Grade 1 or 2. 願顧遞遞廠膚簾膚糧襯 (衊鹹網膚鹹窪餘鹽製壓 ) 更多 | 积极 | 2018-02-26 |